Abivax Presents Third Quarter 2025 Financial Results
- Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027
PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA (PARIS:FR) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today its key financial information for the nine months ended September 30, 2025. The unaudited interim condensed consolidated financial statements as of and for the three and nine months ending September 30, 2025, reviewed by the Company’s Board of Directors on December 11, 2025, have been reviewed by the Company’s external auditors.
Abivax provided, since the most recently released financial results press release, the following key updates on its business and operational goals in press releases published:
- On September 23, 2025, a press release titled “Abivax Announces Presentation of Late-Breaking Abstract of Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting”
- On September 29, 2025, a press release titled “Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting”
- On October 5, 2025, a press release titled “Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data”
- On October 6, 2025, a press release titled “Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies”
- On November 3, 2025, a press release titled “Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis”
Third Quarter 2025 Financial Highlights (IFRS figures)
(Consolidated, unaudited results)
| Statements of Loss* | Nine months ended September 30, |
Change | |||
| in millions of euros | 2025 | 2024 | |||
| Total operating income | 4.1 | 8.1 | (4.0) | ||
| Total operating expenses | |||||
| of which Research and Development costs | (133.4) | (107.9) | (25.4) | ||
| of which Sales and Marketing costs | (3.4) | (5.1) | 1.7 | ||
| of which General and Administrative costs | (41.8) | (25.3) | (16.5) | ||
| Operating loss | (174.4) | (130.2) | (44.2) | ||
| Financial gain (loss) | (79.7) | (6.7) | (73.1) | ||
| Net loss for the period | (254.1) | (136.9) | (117.3) | ||
| Statements of Financial Position* | September 30, 2025 | December 31, 2024 | Change | ||
| in millions of euros | |||||
| Net financial position | 543.3 | 53.4 | 489.9 | ||
| of which other current financial assets and other current receivables and assets* | 27.6 |